当前位置: X-MOL 学术ChemMedChem › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Development of an Efficient Dual‐Action GST‐Inhibiting Anticancer Platinum(IV) Prodrug
ChemMedChem ( IF 3.6 ) Pub Date : 2018-05-28 , DOI: 10.1002/cmdc.201800105
Keefe Guang Zhi Lee 1 , Maria V. Babak 1 , Andrea Weiss 2 , Paul J. Dyson 3 , Patrycja Nowak-Sliwinska 2 , Diego Montagner 4 , Wee Han Ang 1
Affiliation  

The cytotoxicity of cisplatin (cDDP) is enhanced when co‐administered with ethacrynic acid (EA), a glutathione S‐transferase (GST) inhibitor. A PtIV–EA conjugate containing a cDDP core and two axial ethacrynate ligands (compound 1) was shown to be an excellent inhibitor of GST, but did not readily release a PtII species to exert a synergistic cytotoxic effect. In this study, a redesigned PtIV construct composed of a cDDP core with one axial ethacrynate ligand and one axial hydroxido ligand (compound 2) was prepared and shown to overcome the limitations of compound 1. The EA ligand in 2 is readily released in vitro together with a cytotoxic PtII species derived from cisplatin, working together to inhibit cell proliferation in cDDP‐resistant human ovarian cancer cells. The in vitro activity translates well in vivo with 2, showing effective (∼80 %) inhibition of tumor growth in a human ovarian carcinoma A2780 tumor model, while showing considerably lower toxicity than cisplatin, thus validating the new design strategy.

中文翻译:

高效的抑制GST的双重作用的抗癌铂(IV)前药的开发

与谷胱甘肽S-转移酶(GST)抑制剂乙炔酸(EA)并用时,顺铂(cDDP)的细胞毒性增强。含有cDDP核和两个轴向乙酰胺酸酯配体(化合物1)的Pt IV -EA共轭物被证明是GST的优良抑制剂,但不容易释放Pt II物质发挥协同细胞毒性作用。在这项研究中,由cDDP核心与一个轴向乙二酸酯配体和一个轴向羟基配体(化合物2)组成的重新设计的Pt IV构造被制备,并显示出克服了化合物1的局限性。在EA配体2在体外容易地释放与细胞毒性的Pt一起II顺铂衍生的物种共同作用,以抑制耐cDDP的人类卵巢癌细胞的细胞增殖。体外活性在体内能以2很好地翻译,在人类卵巢癌A2780肿瘤模型中显示出对肿瘤生长的有效抑制(〜80%),同时显示出比顺铂低得多的毒性,从而验证了新的设计策略。
更新日期:2018-05-28
down
wechat
bug